II期临床-话题@MedSci

#II期临床#

478篇内容 | 2583人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1524687, encodeId=129a152468eba, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=赛诺菲：Dupixent（dupilumab）治疗严重慢性鼻窦炎、鼻息肉的两项III期临床试验取得了积极成果 , objectType=article, longId=161247, objectId=7cfc16124ea4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7cfc16124ea4, replyNumber=0, likeNumber=58, createdTime=2019-02-28, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7cfc16124ea4, moduleTitle=赛诺菲：Dupixent（dupilumab）治疗严重慢性鼻窦炎、鼻息肉的两项III期临床试验取得了积极成果 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7cfc16124ea4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524686, encodeId=5f8f1524686b3, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=双重抗血小板疗法(替格瑞洛联合阿司匹林)在控制不良心血管事件的III期临床试验中大获成功, objectType=article, longId=161192, objectId=ee9f16119219, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee9f16119219, replyNumber=0, likeNumber=53, createdTime=2019-02-28, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee9f16119219, moduleTitle=双重抗血小板疗法(替格瑞洛联合阿司匹林)在控制不良心血管事件的III期临床试验中大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee9f16119219)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524685, encodeId=1451152468521, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=PTR-01（BBP-589）治疗隐性营养不良性大疱性表皮松解症的I/II期临床正式开展, objectType=article, longId=161017, objectId=3f0216101ea6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f0216101ea6, replyNumber=0, likeNumber=0, createdTime=2019-02-26, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f0216101ea6, moduleTitle=PTR-01（BBP-589）治疗隐性营养不良性大疱性表皮松解症的I/II期临床正式开展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f0216101ea6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524684, encodeId=c5d01524684c4, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=辉瑞和礼来公司汇报了NGF抑制剂tanezumab在慢性腰痛中的积极III期临床数据, objectType=article, longId=160662, objectId=4eb716066282, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4eb716066282, replyNumber=0, likeNumber=77, createdTime=2019-02-22, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4eb716066282, moduleTitle=辉瑞和礼来公司汇报了NGF抑制剂tanezumab在慢性腰痛中的积极III期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4eb716066282)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524683, encodeId=84441524683ff, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=默克Keytruda治疗晚期肝癌的III期临床试验失败告终, objectType=article, longId=160650, objectId=909e1606500c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=909e1606500c, replyNumber=0, likeNumber=64, createdTime=2019-02-22, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=909e1606500c, moduleTitle=默克Keytruda治疗晚期肝癌的III期临床试验失败告终, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=909e1606500c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524682, encodeId=965015246820e, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=J Thorac Oncol：放疗分割方式是否与脑转移相关？III期临床研究CONVERT给你答案, objectType=article, longId=160563, objectId=3f571605635b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f571605635b, replyNumber=0, likeNumber=58, createdTime=2019-02-21, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f571605635b, moduleTitle=J Thorac Oncol：放疗分割方式是否与脑转移相关？III期临床研究CONVERT给你答案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f571605635b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524681, encodeId=d434152468175, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Gyroscope宣布其新型视网膜基因疗法正在进行老年性黄斑变性（AMD）的I / II期临床研究, objectType=article, longId=160548, objectId=fcad160548ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcad160548ce, replyNumber=0, likeNumber=92, createdTime=2019-02-21, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcad160548ce, moduleTitle=Gyroscope宣布其新型视网膜基因疗法正在进行老年性黄斑变性（AMD）的I / II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcad160548ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524680, encodeId=94291524680ee, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=III期临床试验证实Keytruda联用阿西替尼显著降低晚期肾癌的死亡率, objectType=article, longId=160546, objectId=fa9316054665, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa9316054665, replyNumber=0, likeNumber=58, createdTime=2019-02-21, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa9316054665, moduleTitle=III期临床试验证实Keytruda联用阿西替尼显著降低晚期肾癌的死亡率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa9316054665)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524679, encodeId=a2c215246e9a2, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=FDA批准新型心血管支持液VBI-1进入II期临床试验, objectType=article, longId=160532, objectId=d280160532df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d280160532df, replyNumber=0, likeNumber=61, createdTime=2019-02-21, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d280160532df, moduleTitle=FDA批准新型心血管支持液VBI-1进入II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d280160532df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524678, encodeId=12b015246e8f3, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=默沙东将开展Keytruda治疗前列腺癌的3个III期临床试验, objectType=article, longId=160438, objectId=5b3116043863, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b3116043863, replyNumber=0, likeNumber=76, createdTime=2019-02-20, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b3116043863, moduleTitle=默沙东将开展Keytruda治疗前列腺癌的3个III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b3116043863)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524677, encodeId=31df15246e70c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=II期临床研究FUZE评估Debio 1347治疗晚期实体瘤的疗效, objectType=article, longId=160427, objectId=61c716042e5f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61c716042e5f, replyNumber=0, likeNumber=67, createdTime=2019-02-20, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61c716042e5f, moduleTitle=II期临床研究FUZE评估Debio 1347治疗晚期实体瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61c716042e5f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524676, encodeId=6d7f15246e66d, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=以胸腺素β4为活性成分的新型治疗肽正进行干眼症的III期临床试验, objectType=article, longId=160421, objectId=524e160421b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=524e160421b4, replyNumber=0, likeNumber=70, createdTime=2019-02-20, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=524e160421b4, moduleTitle=以胸腺素β4为活性成分的新型治疗肽正进行干眼症的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=524e160421b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524675, encodeId=024915246e563, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=III期临床试验证明恩杂鲁胺与雄激素剥夺疗法（ADT）联合使用明显改善转移性前列腺癌的存活率, objectType=article, longId=160414, objectId=ea1416041497, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea1416041497, replyNumber=0, likeNumber=63, createdTime=2019-02-20, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea1416041497, moduleTitle=III期临床试验证明恩杂鲁胺与雄激素剥夺疗法（ADT）联合使用明显改善转移性前列腺癌的存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea1416041497)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524674, encodeId=9d5f15246e4f4, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Helsinn和MEI Pharma公布Pracinostat联合阿扎胞苷治疗AML的II期临床数据, objectType=article, longId=160407, objectId=b51a16040ede, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b51a16040ede, replyNumber=0, likeNumber=64, createdTime=2019-02-20, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b51a16040ede, moduleTitle=Helsinn和MEI Pharma公布Pracinostat联合阿扎胞苷治疗AML的II期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b51a16040ede)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524673, encodeId=2b5215246e353, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=治疗粘多糖贮积症的基因疗法LYS-SAF302 的II/III期临床试验AAVance正式开始, objectType=article, longId=160342, objectId=a54e16034284, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a54e16034284, replyNumber=0, likeNumber=55, createdTime=2019-02-19, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a54e16034284, moduleTitle=治疗粘多糖贮积症的基因疗法LYS-SAF302 的II/III期临床试验AAVance正式开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a54e16034284)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524672, encodeId=362b15246e23a, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=JCO：卡铂和紫杉醇对未知原发癌患者的部位特异性治疗：II期临床试验, objectType=article, longId=158471, objectId=e6371584e194, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6371584e194, replyNumber=0, likeNumber=90, createdTime=2019-01-21, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6371584e194, moduleTitle=JCO：卡铂和紫杉醇对未知原发癌患者的部位特异性治疗：II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6371584e194)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524671, encodeId=2f4915246e166, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=信达生物宣布达伯舒®一线胃癌III期临床研究完成首例患者给药, objectType=article, longId=158309, objectId=2e6815830948, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e6815830948, replyNumber=0, likeNumber=96, createdTime=2019-01-19, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e6815830948, moduleTitle=信达生物宣布达伯舒®一线胃癌III期临床研究完成首例患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e6815830948)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524670, encodeId=7fef15246e068, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Netarsudil眼科解决方案在II期临床中取得积极成果, objectType=article, longId=157813, objectId=d56715e8132b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d56715e8132b, replyNumber=0, likeNumber=68, createdTime=2019-01-12, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d56715e8132b, moduleTitle=Netarsudil眼科解决方案在II期临床中取得积极成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d56715e8132b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524669, encodeId=27891524669d9, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=II期j临床试验成功而III期临床失败的案例教训, objectType=article, longId=157416, objectId=f2d315e41677, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2d315e41677, replyNumber=0, likeNumber=53, createdTime=2019-01-07, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2d315e41677, moduleTitle=II期j临床试验成功而III期临床失败的案例教训, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2d315e41677)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524668, encodeId=836f1524668c1, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Incyte宣布开展Ruxolitinib的III期临床试验, objectType=article, longId=156672, objectId=aeee1566e228, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aeee1566e228, replyNumber=0, likeNumber=52, createdTime=2018-12-27, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aeee1566e228, moduleTitle=Incyte宣布开展Ruxolitinib的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aeee1566e228)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床

2020-05-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

赛诺菲：Dupixent（dupilumab）治疗严重慢性鼻窦炎、鼻息肉的两项III期临床试验取得了积极成果 

2019-02-28

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

双重抗血小板疗法(替格瑞洛联合阿司匹林)在控制不良心血管事件的III期临床试验中大获成功

2019-02-28

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

PTR-01（BBP-589）治疗隐性营养不良性大疱性表皮松解症的I/II期临床正式开展

2019-02-26

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

辉瑞和礼来公司汇报了NGF抑制剂tanezumab在慢性腰痛中的积极III期临床数据

2019-02-22

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

默克Keytruda治疗晚期肝癌的III期临床试验失败告终

2019-02-22

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

J Thorac Oncol：放疗分割方式是否与脑转移相关？III期临床研究CONVERT给你答案

2019-02-21

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Gyroscope宣布其新型视网膜基因疗法正在进行老年性黄斑变性（AMD）的I / II期临床研究

2019-02-21

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

III期临床试验证实Keytruda联用阿西替尼显著降低晚期肾癌的死亡率

2019-02-21

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

FDA批准新型心血管支持液VBI-1进入II期临床试验

2019-02-21

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

默沙东将开展Keytruda治疗前列腺癌的3个III期临床试验

2019-02-20

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

II期临床研究FUZE评估Debio 1347治疗晚期实体瘤的疗效

2019-02-20

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

以胸腺素β4为活性成分的新型治疗肽正进行干眼症的III期临床试验

2019-02-20

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

III期临床试验证明恩杂鲁胺与雄激素剥夺疗法（ADT）联合使用明显改善转移性前列腺癌的存活率

2019-02-20

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Helsinn和MEI Pharma公布Pracinostat联合阿扎胞苷治疗AML的II期临床数据

2019-02-20

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

治疗粘多糖贮积症的基因疗法LYS-SAF302 的II/III期临床试验AAVance正式开始

2019-02-19

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

JCO：卡铂和紫杉醇对未知原发癌患者的部位特异性治疗：II期临床试验

2019-01-21

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

信达生物宣布达伯舒®一线胃癌III期临床研究完成首例患者给药

2019-01-19

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Netarsudil眼科解决方案在II期临床中取得积极成果

2019-01-12

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

II期j临床试验成功而III期临床失败的案例教训

2019-01-07

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Incyte宣布开展Ruxolitinib的III期临床试验

2018-12-27

科室
- - 订阅+
  - 更多科室
工具
服务